Review Article

Serine Proteases of Malaria Parasite Plasmodium falciparum: Potential as Antimalarial Drug Targets

Asrar Alam

Department of Biological Sciences, Tata Institute of Fundamental Research, Homi Bhabha Road, Colaba, Mumbai-400005, India

Correspondence should be addressed to Asrar Alam; asraralam22@yahoo.co.in

Received 25 October 2013; Revised 2 January 2014; Accepted 7 January 2014; Published 11 March 2014

Copyright © 2014 Asrar Alam. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Malaria is a major global parasitic disease and a cause of enormous mortality and morbidity. Widespread drug resistance against currently available antimalarials warrants the identification of novel drug targets and development of new drugs. Malarial proteases are a group of molecules that serve as potential drug targets because of their essentiality for parasite life cycle stages and feasibility of designing specific inhibitors against them. Proteases belonging to various mechanistic classes are found in P. falciparum, of which serine proteases are of particular interest due to their involvement in parasite-specific processes of egress and invasion. In P. falciparum, a number of serine proteases belonging to chymotrypsin, subtilisin, and rhomboid clans are found. This review focuses on the potential of P. falciparum serine proteases as antimalarial drug targets.

1. Global Malaria Burden and Need for Development of Novel Antimalarials

Malaria caused by protozoan parasite Plasmodium is a major global parasitic disease [1]. Malaria in humans is caused by five Plasmodium species, namely, P. falciparum, P. vivax, P. ovale, P. malariae, and P. knowlesi. Of these, P. falciparum is the causative agent of severe malaria and the major cause of malaria-related fatality.

According to World Malaria Report of 2013, there were an estimated 207 million clinical cases of malaria in 2012 and an estimated 627,000 deaths, with about 90% of deaths occurring in sub-Saharan Africa. International efforts to control malaria have resulted in significant reduction of malaria-related deaths. Between 2000 and 2012, malaria-related deaths reduced by 29% globally and 31% in the WHO African Region [2]. Methods used to prevent the spread of the disease or to protect individuals in areas where malaria is endemic include therapeutic and prophylactic drugs, mosquito eradication, and prevention of mosquito bites by using insecticide-treated nets (ITNs), indoor residual spray, and larval control [2].

Early antimalarial agents were isolated from natural products. Bark of the cinchona tree and extracts of the wormwood plant were among the first effective antimalarials. Quinoline compound chloroquine has been the most widely used drug until recently. Resistance to chloroquine started in Africa in the 1980s, causing tremendous resurgence of malaria burden [3, 4]. Chloroquine resistance prompted many countries to adopt sulfadoxine-pyrimethamine (SP) as the first-line antimalarial but resistant P. falciparum populations were selected quickly in Africa, Southeast Asia, and South America. It was abandoned after only 5 years of use in Southeast Asia [5, 6]. Due to widespread resistance to the available antimalarials, artemisinin-based combination therapies (ACTs) were introduced in Asia, Africa, and South America. The artemisinins are potent and rapidly acting antimalarials derived from the Chinese sweet wormwood plant, Artemisia annua [7, 8]. Due to their short duration of action, artemisinins cannot be administered alone, which results in recrudescence parasitemia [9]; however, they can be administered as ACTs over three days in the combinations with longer-acting antimalarials in the forms of artemether-lumefantrine, amodiaquine-artesunate, and mefloquine-artesunate [10]. Despite the effectiveness of ACTs, use of artemisinin monotherapy resulted in emergence of drug-resistant P. falciparum parasites in Cambodia-Thailand border region [11, 12]. According to WHO, till now drug resistance has been reported in three
Plasmodium species, *P. falciparum, P. vivax*, and *P. malariae* [13].

Currently treatment of malaria is effected mainly through the administration of chloroquine, SP, and ACTs. Prophylactic drugs include chloroquine, primaquine, mefloquine, doxycycline, and malarone (atovaquone and proguanil) [14]. Despite the availability of antimalarials for both treatment and prophylaxis, the spread of resistance and paucity of more antimalarials warrants the need for identification of new drug targets and development of novel drugs.

2. Proteases as Antimalarial Drug Targets

Proteases constitute a ubiquitous and highly abundant group of catalytic and regulatory molecules having widespread roles in living systems. They are primarily involved in protein turnover to their constituent amino acids to generate the building blocks for new proteins and digestion of dietary proteins in higher organisms. Besides, protein activation by limited proteolysis is a common means of regulation of many physiological processes [15]. Proteases constitute the major virulence factors in various parasitic diseases such as schistosomiasis, malaria, leishmaniasis, Chagas disease, and African sleeping sickness. Some well-characterized examples of the roles of proteases in parasite pathogenesis include their involvement in the invasion of host cells, degradation of hemoglobin and other blood proteins, immune evasion, and activation of inflammation [16]. In this context, they are crucial for the pathogenic organisms both for their survival and the diseases they cause. Their potential as drug targets is underscored by the feasibility of designing specific inhibitors against them.

Proteases recognize an optimum peptide sequence and catalyze its cleavage at the active site. Selective inhibitors targeting the active sites can be developed. Besides the active sites, exosites and allosteric sites also participate in substrate recognition. Hence, selective inhibitors targeting these sites can also be developed [17].

Protease inhibitors have been successfully used as drugs against human immunodeficiency virus (HIV) [18] and hepatitis C virus (HCV) [19] and in treatment of hypertension [20] and coagulopathies [21]. The active sites of proteases have been successfully targeted against viruses HIV and HCV and angiotensin-converting enzyme in hypertension [22, 23]. Targeting the active site is not always feasible due to homology with the host enzymes. For example, in many cancers, development of protease inhibitor-based drugs has been challenging due to the difficulty in selectively targeting the active sites. In such cases, allosteric sites could be targeted to achieve the goals [17]. Malaria parasite is the most important member of the parasites of phylum Apicomplexa, which invade the host cell and reside in intracellular niche that is protected from host defenses and provides a rich source of nutrient. Asexual erythrocytic life cycle of malaria parasite is responsible for the clinical symptoms of malaria. It starts with the invasion of erythrocytes by the merozoites released from liver. The intraerythrocytic parasite feeds on host hemoglobin and develops from small ring stage form to a relatively large and metabolically active trophozoite stage parasite, which then transforms to multinucleated schizont. Inhibitor-based studies have shown that cysteine, aspartic, metallo, and serine protease activities are crucial for completion of this cycle [24]. Several previous studies have implicated a functional role of serine proteases in egress and invasion at blood stages [25–27].

3. *P. falciparum* Serine Proteases

Serine proteases are widely dispersed in organisms through evolution and have diverse functions. They have been grouped into thirteen clans [28]. Chymotrypsin/trypsin-like and subtilisin-like serine proteases are two major clans of serine proteases, which have highly similar arrangement of catalytic triad Asp, His, and Ser residues and radically different protein scaffolds, that is, β/β for chymotrypsin and α/β for subtilisin [29]. A number of serine proteases belonging to chymotrypsin, subtilisin, and rhomboid protease clans are found in *P. falciparum* genome. A list of *P. falciparum* serine proteases along with their orthologs and putative functions is presented in Table S1 (Supplementary Materials available online at http://dx.doi.org/10.1155/2014/453186). These pro-teases are expressed in a temporally regulated manner at the asexual and sexual stages of the parasite life cycle [30–32]. Table S2 presents the microarray and mass spectrometry based expression profiles of *P. falciparum* serine proteases. Some of these proteases are known to be essential for parasite development at the erythrocytic and exoerythrocytic stages suggesting their potential as targets for therapeutic intervention.

3.1. *P. falciparum* Chymotrypsin-Like Proteases. Two genes encoding for serine proteases of chymotrypsin-like clan (PlasmoDB IDs: PF3D7_0807700 and PF3D7_0812200) were identified in *P. falciparum* genome. PF3D7_0807700 is homologous to DegP heat shock protein family [33]. Since DegP acts as a chaperone at low temperature and protease at elevated temperature, its role in extracellular process related to invasion is unlikely. The second putative chymotrypsin-like serine protease PF3D7_0812200 possesses PDX2 domain besides the trypsin domain. This domain is found in prokaryotic, viral, and eukaryotic signaling proteins having GTPase activity [34], known to anchor transmembrane proteins to cytoskeleton and assembly of signaling complexes. This protease is also unlikely to be directly involved in invasion.

3.2. *P. falciparum* Subtilisin-Like Proteases. Three genes encoding for proteases of another major clan, subtilisin-like proteases or subtilases (clan SB) [35], are found in *P. falciparum* genome known as PfSUB1, 2, and 3. All of them are highly expressed at late asexual blood stages [31]. Of these, PfSUB1 and 2 have been extensively characterized and implicated in egress and invasion during asexual blood stage life cycle of the parasite [26, 27, 36]. PfSUB3 is the least characterized member and preliminary reports have confirmed the in vitro serine protease activity of PfSUB3
and also identified a multifunctional parasite protein, profilin, as its interacting partner [37, 38].

3.2.1. *P. falciparum* Subtilisin-Like Protease 1 (PfSUB1). PfSUB1 (PlasmoDB ID: PF3D7_050700 and MEROPS identification number S08.012) is the first identified member of *P. falciparum* subtilases. The primary structure of PfSUB1 classifies it in a small group of bacterial-like eukaryotic subtilases [29, 35], PfSUB1 undergoes two major intracellular processing steps during maturation. The first one takes place inside the lumen of endoplasmic reticulum and converts the earliest detectable 82 kDa form into a 54 kDa form (p54) [39]. The second, brefeldin A-sensitive processing step, is the conversion of p54 to intracellular 47 kDa terminal processing product (p47); both p54 and p47 contain the predicted catalytic domain [40].

Expression of codon-optimized PfSUB1 gene in recombinant baculovirus-infected insect cells resulted in the secretion of the processed form (p54) [39]. N-terminal radiosequencing of the *in vitro* translated protein showed the cleavage between Asp219 and Asn220 within the sequence Leu-Val-Ser-Ala-Asp-Ile-Ser. This highly restricted substrate specificity of PfSUB1 is suggestive of a very specialized and nondegradative biological function in the parasite [39, 41]. A substantial fraction of insect cell-secreted p54 was found bound to its 31 kDa propeptide (rp31), which was a highly selective, high-affinity inhibitor of the protease with dissociation constant in nanomolar range (Ki ∼ 12.5 nM) [39]. Truncation of 11 residues from the C-terminal of rp31 substantially reduced inhibition of PfSUB1 activity [42]. Since subtilase propeptides are specific inhibitors of their cognate proteases [43–47], the inhibitory peptides from the proregion will facilitate designing of specific inhibitors of the protease.

Many *Plasmodium* proteins possess structural insertions not found in their homologs from other genera [48, 49]. These insertions may provide targets for highly selective therapies against *P. falciparum*. Comparison of PfSUB1 primary structure with its orthologs and related bacterial subtilins revealed the presence of both high and low complexity insertions that are predicted to form surface strand or loop structures. Site-directed mutagenesis, deletion of the whole loop insertions, or strategic replacements revealed that the majority of the loop insertions are critical for the activity of the protease [50].

PfSUB1 gene was found to be refractory to deletion in blood stages. It was stored in apical organelles, distinct from those involved in erythrocyte invasion and termed as “exonemes” [26]. During the final stage of schizont maturation, it was discharged into the parasitophorous vacuole (PV) and triggered a series of proteolytic events resulting in merozoite egress [27]. In an attempt to identify the mediators of egress, Arastu-Kapur et al. tested the effect of a library of 1,200 focused serine and cysteine protease inhibitors on blood stage malaria parasite growth. Using the hits from library screening, they identified PfSUB1 and dipeptidyl aminopeptidase 3 (DPAP3) as the primary regulators of egress. Inhibition of PfSUB1 and DPAP3 caused a block in schizont rupture [27] whereas at a relatively lower concentration of the inhibitor, defective merozoites were released [51]. DPAP3 caused maturation of PfSUB1 [27]. The mature PfSUB1 caused processing of parasitophorous vacuolar proteins SERA5 [27] and SERA6 [52], which are implicated in merozoite egress.

Merozoite surface protein 1 (MSPI) complex is a large glycosylphosphatidylinositol (GPI)-anchored protein complex, which is comprised of MSP1 and its associated partner proteins MSP6 and MSP7. During erythrocyte invasion, the initial low affinity interaction with the host cell takes place through this complex [53–55]. Proteolytic processing (primary processing) of this complex is necessary for initial low affinity interaction between the host and parasite and erythrocyte invasion. At a later stage, another processing of this complex is required for movement of the merozoite inside the host cell (secondary processing) [36]. PfSUB1 carries out the primary processing of MSP1 complex in the parasitophorous vacuole in a spatiotemporally regulated manner [56]. Besides, PfSUB1 also cleaves a number of merozoite and parasitophorous vacuolar proteins [57]. Besides blood stages, SUB1 is also essential for liver developmental stages. Conditional knockout of *Plasmodium berghei* SUB1 (PbSUB1) revealed that SUB1, although not essential for early liver stage development, was essential for development of liver stage schizonts and production of merozoites [58]. Conditional mutagenesis studies showed that PbSUB1-deficient merozoites were unable to egress from the hepatocytes [59].

Recently attempts have been made to identify PfSUB1 inhibitors. Maslinic acid (MA), a low toxic natural pentacyclic triterpene, was found to inhibit the *P. falciparum* blood stage transition from ring to schizont stage by a multitargeted mechanism. MA was found to inhibit the proteolytic processing of the MSP1 complex, probably by targeting PfSUB1 [60]. Characterization of PfSUB1 orthologs from *P. vivax*, *P. knowlesi*, and *P. berghei* revealed that although there are a number of unusual features of the SUB1 substrate binding cleft, cleavage sites in parasite substrates in these proteases are conserved. Two peptidyl alpha-ketoamide inhibitors of PfSUB1 inhibited all its orthologs suggesting that small molecule inhibitors can be developed against this protease [61]. A molecular dynamics simulation study of binding of known PfSUB1 substrate peptides based on its prodomain revealed that the prime and nonprime sides of the scissile bond make the major contribution to the binding free energy. It comprises the peptide residues P4 to P2 making this region of potential interest for designing peptidomimetic inhibitors against PfSUB1 [62]. Given its essentiality for parasite blood and liver stages, proteolytic activity on multiple parasite proteins, and role in egress and invasion, PfSUB1 qualifies as an attractive antimalarial drug target.

3.2.2. *P. falciparum* Subtilisin-Like Protease 2. *P. falciparum* subtilisin-like protease 2 (PfSUB2) (PlasmoDB ID: 248 PF3D7_1136900 and MEROPS identification number: S08.013) is a type I 249 transmembrane protein and expressed at late asexual blood stages. Attempts to disrupt *P. berghei* ortholog of PfSUB2 (PbSUB2) by double-crossover integration have been unsuccessful, suggesting the potential
of PfSUB2 as a drug target [63]. It is secreted into merozoite apical organelles "micromeres" and plays a critical role in merozoite invasion of red blood cells (RBCs) [36].

PfSUB2 causes shedding of merozoite adhesins MSP1 and apical membrane antigen 1 (AMA1) at a juxtamembrane site during invasion [64]. Cleavage of MSP1 by PfSUB2 takes place distal to an epidermal growth factor-like domain at its C-terminal called MSP1\textsubscript{19} [53]. MSP1\textsubscript{19} remains bound to the merozoite surface and it is the only part of MSP1, which enters into the host cell. Cleavage of AMA1 takes places 29 residues away from the transmembrane domain, releasing the bulk of the ectodomain. In this way, the juxtamembrane "stubs" along with its cognate transmembrane domain (TMD) and cytoplasmic domain enters into the host cell [65]. Shedding of these proteins is essential for productive invasion [65–67]. Since PfSUB2 causes the shedding of both MSP1 and AMA1 at the moving junction during erythrocyte invasion, it is termed as "merozoite surface sheddase" (MESH). This protein has not been expressed in recombinant proteolytically active form but shows the MESH activity in purified merozoites. It translocates from the anterior to the posterior end of the merozoite in an actin-dependent movement as the merozoites enter into the host erythrocyte [36].

Like PfSUB1, PfSUB2 also undergoes proteolytic processing in the parasite, which could be probable maturation events. The open reading frame encoding for PfSUB2 was \textit{in vitro} translated, which revealed that the 154.8 kDa primary translated product (SUB2p) underwent rapid conversion to 74 kDa intermediate species (SUB2\textsubscript{i}) which was quantitatively converted to terminal 72 kDa species (SUB2\textsubscript{T}) [68]. The prodomain of PfSUB2 has been found to be a selective inhibitor of its "sheddase" activity [36]. Nuclear magnetic resonance (NMR) structure of PfSUB2 prodomain identified a likely catalytic domain-binding interface region in it, which could be exploited to design peptidomimetic inhibitors against the protease [69]. Essentiality of the protease for parasite survival, involvement in RBC invasion, and the initial findings suggesting the feasibility of designing inhibitors against the protease make PfSUB2 a promising drug target against malaria.

3.2.3. \textit{P. falciparum} Subtilisin-Like Protease 3. \textit{P. falciparum} subtilisin-like protease 3 (PfSUB3) (PlasmoDB ID: PF3D7_0507200 and MEROPS identification number: S08.122) is the third \textit{P. falciparum} subtilase. PfSUB3 is the least studied member of \textit{P. falciparum} subtilases. It is also highly expressed at late asexual blood stages [31]. The full-length PfSUB3 gene encodes an 88 kDa protein, the 25 kDa C-terminal region of which has been shown to possess serine protease activity [37]. Yeast two-hybrid screening has revealed parasite profilin (PfPRF), a cytoskeletal and proinflammatory molecule, as an interacting partner of PfSUB3. PfPRF was found to induce the secretion of proinflammatory cytokines IL-12 and TNF-\textalpha from mouse bone marrow-derived dendritic cells. PfSUB3 showed proteolytic activity on PfPRF \textit{in vitro} assays and caused cleavage of PfPRF into multiple fragments of smaller sizes, which were hydrolyzed by increasing concentration of PfSUB3 [38]. It is still not clear if this proteolytic activity causes maturation of PfPRF or degradation under physiological conditions. Given the serine protease activity of PfSUB3 and multiple physiological functions of PfPRF, namely, motility, egress, and induction, of proinflammatory cytokines, its role in the related processes needs to be explored [38].

3.3. \textit{P. falciparum} Rhomboid Proteases. Rhomboid proteases are intramembranous serine proteases with their catalytic triad embedded within the membrane bilayer, surrounded by a hydrophilic cavity formed by a protein ring [70]. Nine rhomboid protease genes are found in \textit{P. falciparum} genome. \textit{P. falciparum} rhomboids are largely uncharacterized till date.

Two characterized members of \textit{P. falciparum} rhomboids are PfROM1 and PfPROM4. PfROM1 localizes to a thread-like apical organelle of blood stage merozoites termed as "mononeme" [71] and on the surface of sporozoites after salivary gland invasion [72]. \textit{Plasmodium yoelii} ROM1 deficient parasites were attenuated during erythrocytic and hepatic stages and defective in parasitophorous vacuole (PV) development [73]. PfROM1 and PfPROM4 helped in merozoite invasion by catalyzing the intramembrane cleavage of the merozoite adhesin AMA1 [65, 74] and erythrocyte binding antigen 175 (EBA-175), respectively [75]. PfROM1 and/or 4 were able to cleave a variety of adhesins involved in host parasite interaction within the transmembrane domains [74]. Although initial reports on these proteases are suggestive of their importance for parasite development, they still remain to be extensively characterized and assessed for their therapeutic value.

4. Conclusion

\textit{P. falciparum} serine proteases are of particular interest as potential antimalarial drug targets due to their role in the processes of egress and invasion at erythrocytic and preerythrocytic stages, two critical checkpoints where the parasite development can be blocked. Involvement of parasite serine proteases in processing of parasite molecules involved in molecular interactions during parasite invasion and cleavage of the transmembrane adhesins for the invasion make them attractive drug targets. Liver stages, although clinically silent, are potential targets of drug and vaccine intervention due to their low abundance and distinct metabolism. Study of proteases expressed at liver stages is an exciting area of research. A schematic diagram of role of \textit{P. falciparum} serine proteases at asexual blood stages and liver stages is shown in Figure 1.

Extensive biochemical and structural characterization of these molecules and high throughput screening for small molecules inhibitors will lead to the way of development of novel drugs directed against these proteases. Besides, the peptidomimetic inhibitors based on the inhibitory region of the prodomains can also be developed.
Interdisciplinary Perspectives on Infectious Diseases

Figure 1: Role of serine proteases at asexual blood stages (a) and liver stages of Plasmodium falciparum (b). Subtilisin-like proteases are essential for merozoite invasion and egress in blood stages, liver stage schizont development and subsequent liver stage merozoite egress. Rhomboid protease activities are supposed to be involved in invasion of RBC and liver.

**Conflict of Interests**

The author declares that there is no conflict of interests regarding the publication of this paper.

**Acknowledgments**

Data sources for PlasmoDB Version 10 are gratefully acknowledged. The author is thankful to Professor Athar Chishti, Tufts University, USA, for proofreading the paper.

**References**

[1] J. G. Breman, “The ears of the hippopotamus: manifestations, determinants, and estimates of the malaria burden,” *The American Journal of Tropical Medicine and Hygiene*, vol. 64, no. 1-2, pp. 1-11, 2001.

[2] WHO, “World malaria report,” 2013.

[3] J. F. Trape, F. Legros, P. Ndiaye et al., “Chloroquine-resistant *Plasmodium falciparum* malaria in Senegal,” *Transactions of the Royal Society of Tropical Medicine and Hygiene*, vol. 83, no. 6, p. 761, 1989.

[4] J. R. Zucker, T. K. Ruebush II, C. Obonyo, J. Otieno, and C. C. Campbell, “The mortality consequences of the continued use of chloroquine in Africa: experience in Siaya, Western Kenya,” *The American Journal of Tropical Medicine and Hygiene*, vol. 68, no. 4, pp. 386–390, 2003.

[5] C. H. Sibley, J. E. Hyde, P. F. G. Sims et al., “Pyrimethamine-sulfadoxine resistance in *Plasmodium falciparum*: what next?” *Trends in Parasitology*, vol. 17, no. 12, pp. 582–588, 2001.

[6] C. Wongsrichanalai, A. L. Pickard, W. H. Wernsdorfer, and S. R. Meshnick, “Epidemiology of drug-resistant malaria,” *Lancet Infectious Diseases*, vol. 2, no. 4, pp. 209–218, 2002.

[7] F. Ter Kuile, N. J. White, P. Holloway, G. Pasvol, and S. Krishna, “*Plasmodium falciparum*: in vitro studies of the pharmacodynamic properties of drugs used for the treatment of severe malaria,” *Experimental Parasitology*, vol. 76, no. 1, pp. 85–95, 1993.

[8] N. J. White, “Qinghaosu (artemisinin): the price of success,” *Science*, vol. 320, no. 5874, pp. 330–334, 2008.

[9] W. Ittarat, A. L. Pickard, P. Rattanasigchan et al., “Recrudescence in artesunate-treated patients with falciparum malaria is dependent on parasite burden not on parasite factors,” *The American Journal of Tropical Medicine and Hygiene*, vol. 68, no. 2, pp. 147–152, 2003.

[10] M. A. Travassos and M. K. Laufer, “Resistance to antimalarial drugs: molecular, pharmacologic, and clinical considerations,” *Pediatric Research*, vol. 65, no. 5, pp. 64R–70R, 2009.

[11] A. M. Dondorp, F. Nosten, P. Yi et al., “Artemisinin resistance in *Plasmodium falciparum* malaria,” *New England Journal of Medicine*, vol. 361, no. 5, pp. 455–467, 2009.

[12] T. J. C. Anderson, S. Nair, S. Nkhoma et al., “High heritability of malaria parasite clearance rate indicates a genetic basis for artemisinin resistance in western Cambodia,” *Journal of Infectious Diseases*, vol. 201, no. 9, pp. 1326–1330, 2010.

[13] WHO, “Global report on antimalarial drug efficacy and drug resistance: 2000–2010,” 2010.

[14] WHO, *Guidelines for the Treatment of Malaria*, 2nd edition, 2010.

[15] B. Turk, “Targeting proteases: successes, failures and future prospects,” *Nature Reviews Drug Discovery*, vol. 5, no. 9, pp. 785–799, 2006.

[16] J. H. McKerrow, C. Caffrey, B. Kelly, P. Loke, and M. Sajid, “Proteases in parasitic diseases,” *Annual Review of Pathology*, vol. 1, pp. 497–536, 2006.

[17] M. Drag and G. S. Salvesen, “Emerging principles in protease-based drug discovery,” *Nature Reviews Drug Discovery*, vol. 9, no. 9, pp. 690–701, 2010.

[18] C. Flexner, G. Bate, and P. Kirkpatrick, “Tipranavir,” *Nature Reviews Drug Discovery*, vol. 4, no. 12, pp. 955–956, 2005.

[19] I. Melnikova, “Hepatitis C therapies,” *Nature Reviews Drug Discovery*, vol. 7, no. 10, pp. 799–800, 2008.

[20] C. G. Smith and J. R. Vane, “The discovery of captopril,” *FASEB Journal*, vol. 17, no. 8, pp. 788–789, 2003.

[21] I. Melnikova, “The anticoagulants market,” *Nature Reviews Drug Discovery*, vol. 8, no. 5, pp. 353–354, 2009.
[22] N. Alkhouri and N. N. Zein, “Protease inhibitors: silver bullets for chronic hepatitis C infection?” Cleveland Clinic Journal of Medicine, vol. 79, no. 3, pp. 213–222, 2012.

[23] A. J. P. Docherty, T. Crabbe, J. P. O’Connell, and C. R. Groom, “Proteases as drug targets,” Biochemical Society Symposium, no. 70, pp. 147–161, 2003.

[24] P. J. Rosenthal, “Hydrolysis of erythrocyte proteins by proteases of malaria parasites,” Current Opinion in Hematology, vol. 9, no. 2, pp. 140–145, 2002.

[25] M. J. Blackman, “Proteases involved in proteolytic invasion by the malaria parasite: function and potential as chemotherapeutic targets,” Current Drug Targets, vol. 1, no. 1, pp. 59–83, 2000.

[26] C. P. Ponting, “Evidence for PDZ domains in bacteria, yeast, and mammals,” Current Opinion in Hematology, vol. 9, no. 2, pp. 140–145, 2002.

[27] S. Yeoh, R. A. O’Donnell, K. Koussis et al., “Subcellular disassembly of a serine protease mediates release of invasive malaria parasites from host erythrocytes,” Cell, vol. 131, no. 6, pp. 1072–1083, 2007.

[28] E. Di Cerah, “Serine proteases,” IUBMB Life, vol. 61, no. 5, pp. 510–515, 2009.

[29] R. J. Siezen and J. A. M. Leunissen, “Subtilases: the superfAMILY of subtilisin-like serine proteases,” Protein Science, vol. 6, no. 3, pp. 501–523, 1997.

[30] M. Llinás, B. L. Puliam, E. D. Wong, J. Zhu, and J. L. DeRisi, “The transcriptome of the intraerythrocytic developmental cycle of Plasmodium falciparum,” PLoS Biology, vol. 1, no. 1, article E5, 2003.

[31] K. G. le Roch, Y. Zhou, P. L. Blair et al., “Discovery of gene function by expression profiling of the malaria parasite life cycle,” Science, vol. 301, no. 5639, pp. 1503–1508, 2003.

[32] J. Withers-Martinez, J. W. Saldanha, B. Ely, F. Hackett, T. O’Connor, and M. J. Blackman, “Expression of recombinant Plasmodium falciparum subtilisin-like protease-1 in insect cells. Characterization, comparison with the parasite protease, and homology modeling,” Journal of Biological Chemistry, vol. 277, no. 33, pp. 29698–29709, 2002.

[33] S. Yeoh, R. A. O’Donnell, K. Koussis et al., “Subcellular discharge of a serine protease mediates release of invasive malaria parasites from host erythrocytes,” Cell, vol. 131, no. 6, pp. 1072–1083, 2007.

[34] P. J. Rosenthal, “Hydrolysis of erythrocyte proteins by proteases of malaria parasites,” Current Opinion in Hematology, vol. 9, no. 2, pp. 140–145, 2002.

[35] M. J. Blackman, “Proteases involved in proteolytic invasion by the malaria parasite: function and potential as chemotherapeutic targets,” Current Drug Targets, vol. 1, no. 1, pp. 59–83, 2000.

[36] Z. Bozdech, M. Llinás, B. L. Pulliam, E. D. Wong, J. Zhu, and J. L. DeRisi, “The transcriptome of the intraerythrocytic developmental cycle of Plasmodium falciparum,” PLoS Biology, vol. 1, no. 1, article E5, 2003.

[37] S. Withers-Martinez, J. W. Saldanha, B. Ely, F. Hackett, T. O’Connor, and M. J. Blackman, “Expression of recombinant Plasmodium falciparum subtilisin-like protease-1 in insect cells. Characterization, comparison with the parasite protease, and homology modeling,” Journal of Biological Chemistry, vol. 277, no. 33, pp. 29698–29709, 2002.

[38] L. Jean, F. Hackett, S. R. Martin, and M. J. Blackman, “Functional characterization of the propeptide of Plasmodium falciparum subtilisin-like protease-1,” Journal of Biological Chemistry, vol. 278, no. 31, pp. 28572–28579, 2003.

[39] Y. Li, Z. Hu, F. Jordan, and M. Inouye, “Functional analysis of the propeptide of subtilisin E as an intramolecular chaperone for protein folding. Refolding and inhibitory abilities of propeptide mutants,” Journal of Biological Chemistry, vol. 270, no. 42, pp. 25127–25132, 1995.

[40] H.-W. Huang, W.-C. Chen, C.-Y. Wu et al., “Asubtilisin-like protein in secretory organelles of Plasmodium falciparum merozoites,” Journal of Biological Chemistry, vol. 273, no. 36, pp. 23398–23409, 1998.
[54] V. K. Goel, X. Li, H. Chen, S.-C. Liu, A. H. Chishti, and S. S. Oh, “Band 3 is a host receptor binding merozoite surface protein 1 during the Plasmodium falciparum invasion of erythrocytes,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 9, pp. 5164–5169, 2003.

[55] X. Li, H. Chen, T. H. Oo et al., “A co-ligand complex anchors Plasmodium falciparum merozoites to the erythrocyte invasion receptor band 3,” Journal of Biological Chemistry, vol. 279, no. 7, pp. 5765–5771, 2004.

[56] M. A. Child, C. Epp, H. Bujard, and M. J. Blackman, “Regulated maturation of malaria merozoite surface protein-1 is essential for parasite growth,” Molecular Microbiology, vol. 78, no. 1, pp. 187–202, 2010.

[57] N. C. S. de Monerri, H. R. Flynn, M. G. Campos et al., “Global identification of multiple substrates for Plasmodium falciparum SUB1, an essential malarial processing protease,” Infection and Immunity, vol. 79, no. 3, pp. 1086–1097, 2011.

[58] C. Suarez, K. Volkman, A. R. Gomes, O. Billker, and M. J. Blackman, “The malarial serine protease SUB1 plays an essential role in parasite liver stage development,” PLoS Pathogens, vol. 9, Article ID e1003811, 2013.

[59] L. Tawk, C. Lacroix, P. Gueirard et al., “A key role for Plasmodium falciparum SUB1 in egress of malaria parasites from host hepatocytes,” The Journal of Biological Chemistry, vol. 288, no. 46, pp. 33336–33346, 2013.

[60] C. Moneriz, J. Mestres, J. M. Bautista, A. Diez, and A. Puyet, “Multi-targeted activity of maslinic acid as an antimalarial natural compound,” FEBS Journal, vol. 278, no. 16, pp. 2951–2961, 2011.

[61] C. Withers-Martinez, C. Suarez, S. Fulle et al., “Plasmodium falciparum subtilisin-like protease 1 (SUB1): insights into the active-site structure, specificity and function of a pan-malaria drug target,” International Journal for Parasitology, vol. 42, no. 6, pp. 597–612, 2012.

[62] S. Fulle, C. Withers-Martinez, M. J. Blackman, G. M. Morris, and P. W. Finn, “Molecular determinants of binding to the Plasmodium subtilisin-like protease 1,” Journal of Chemical Information and Modeling, vol. 53, no. 3, pp. 573–583, 2013.

[63] P. Uzureau, J.-C. Barale, C. J. Janse, A. P. Waters, and C. B. Breton, “Gene targeting demonstrates that the Plasmodium berghei subtilisin PbSUB2 is essential for red cell invasion and reveals spontaneous genetic recombination events,” Cellular Microbiology, vol. 6, no. 1, pp. 65–78, 2004.

[64] J.-C. Barale, T. Blissnich, H. Fujioka et al., “Plasmodium falciparum subtilisin-like protease 2, a merozoite candidate for the merozoite surface protein 1-42 maturase,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 11, pp. 6445–6450, 1999.

[65] S. A. Howell, F. Hackett, A. M. Jongco et al., “Distinct mechanisms govern proteolytic shedding of a key invasion protein in apicomplexan pathogens,” Molecular Microbiology, vol. 57, no. 5, pp. 1342–1356, 2005.

[66] S. L. Fleck, B. Birdsal1, J. Babon et al., “Suramin and suramin analogues inhibit merozoite surface protein-1 secondary processing and erythrocyte invasion by the malaria parasite Plasmodium falciparum,” Journal of Biological Chemistry, vol. 278, no. 48, pp. 47670–47677, 2003.

[67] S. Dutta, D. Haynes, A. Barbosa et al., “Mode of action of invasion-inhibitory antibodies directed against apical membrane antigen 1 of Plasmodium falciparum,” Infection and Immunity, vol. 73, no. 4, pp. 2116–2122, 2005.